369 related articles for article (PubMed ID: 33497760)
1. Chimeric antigen receptor T cell therapy in oncology - Pipeline at a glance: Analysis of the ClinicalTrials.gov database.
Moreno-Cortes E; Forero-Forero JV; Lengerke-Diaz PA; Castro JE
Crit Rev Oncol Hematol; 2021 Mar; 159():103239. PubMed ID: 33497760
[TBL] [Abstract][Full Text] [Related]
2. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
3. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
Sun W; Liang AB; Huang H; Huang XJ
Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
[TBL] [Abstract][Full Text] [Related]
4. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
6. Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.
Pinte L; Cunningham A; Trébéden-Negre H; Nikiforow S; Ritz J
Front Immunol; 2020; 11():608485. PubMed ID: 33658994
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
9. CAR T-cell therapy: Full speed ahead.
Sermer D; Brentjens R
Hematol Oncol; 2019 Jun; 37 Suppl 1():95-100. PubMed ID: 31187533
[TBL] [Abstract][Full Text] [Related]
10. Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors.
Adachi K; Tamada K
Cancer Sci; 2022 Dec; 113(12):4020-4029. PubMed ID: 36047968
[TBL] [Abstract][Full Text] [Related]
11. New targets for CAR T therapy in hematologic malignancies.
Savani M; Oluwole O; Dholaria B
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101277. PubMed ID: 34625226
[TBL] [Abstract][Full Text] [Related]
12. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract][Full Text] [Related]
13. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
15. The Future of Chimeric Antigen Receptor T Cell Therapy.
Smith EL
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1215-1219. PubMed ID: 37442674
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Badar T; Shah NN
Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
[TBL] [Abstract][Full Text] [Related]
18. Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis.
Mohyuddin GR; Atieh T; Ahmed N; Sborov D; McClune B; Abdallah AO; Goodman AM; Aziz M; Allen I; Prasad V
Eur J Cancer; 2021 Oct; 156():164-174. PubMed ID: 34454318
[TBL] [Abstract][Full Text] [Related]
19. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
20. Generation of CAR-T cells using lentiviral vectors.
Poorebrahim M; Quiros-Fernandez I; Fakhr E; Cid-Arregui A
Methods Cell Biol; 2022; 167():39-69. PubMed ID: 35152998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]